Clinical Trials Logo

Pulmonary Fibrosis clinical trials

View clinical trials related to Pulmonary Fibrosis.

Filter by:

NCT ID: NCT06331624 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Biomarker Modulation and the Inhibition of NKT1 Cells by Oral GRI-0621 in Patients With IPF

Start date: March 2024
Phase: Phase 2
Study type: Interventional

This is a Phase 2a, randomized, double-blind, multi-center, placebo-controlled, parallel-design, 2-arm study. Approximately 36 subjects with IPF will be randomized in a 2:1 ratio for GRI-0621 4.5mg or Placebo. GRI-0621 dose of 4.5mg will be compared with placebo following once daily oral administration for 12 weeks. Concurrently, a Sub-Study will be conducted, examining the number and activity of NKT cells in BAL, for up to 12 eligible subjects (across various centers). An interim analysis will be performed when 24 subjects complete 6 weeks of treatment (approximately 8 placebo subjects).

NCT ID: NCT06329401 Not yet recruiting - Clinical trials for Progressive Pulmonary Fibrosis

Phase 2b Study Evaluating the Safety and Efficacy of AP01 in Participants With PPF

Start date: March 2024
Phase: Phase 2
Study type: Interventional

A randomized, double-blind, placebo-controlled clinical study to evaluate the safety and efficacy of 2 doses of AP01 versus placebo on top of standard of care in participants with PPF over 52 weeks.

NCT ID: NCT06327360 Enrolling by invitation - Pulmonary Fibrosis Clinical Trials

Illness Expectations in Pulmonary Fibrosis

CAMFP
Start date: October 10, 2023
Phase:
Study type: Observational

This study aims to delve into the constructs of illness beliefs and expectations among patients with Pulmonary Fibrosis, exploring how these beliefs and expectations may influence the treatment journey, including oxygen therapy, non-invasive ventilation therapy, and pharmacological treatments.

NCT ID: NCT06325696 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

H01 in Adults With Interstitial Lung Disease (The SOLIS Study)

Start date: March 31, 2024
Phase: Phase 2
Study type: Interventional

Background: Interstitial lung disease affects the tissues that aid the transfer of oxygen and carbon dioxide between the air and the bloodstream. The disease can cause fibrosis, a thickening and scarring of lung tissue. Fibrosis often continues getting worse, and most people with this disease die in 3 to 5 years. Objective: To test a study drug (hymecromone) in people with interstitial lung disease or lung fibrosis. Eligibility: People aged 18 years and older with interstitial lung disease or lung fibrosis. Design: Participants will have at least 7 clinic visits over 5 months. Participants will have screening and baseline visits. They will have blood tests and tests of their heart function. They will give a sputum sample. Other tests will include: Spirometry: Participants will breathe in and out through a mouthpiece to measure how much air they can hold in their lungs and how hard they can breathe. Diffusion capacity of lungs for carbon monoxide: Participants will breathe in a gas that contains a small amount of carbon monoxide. Then they will breathe through a mouthpiece. This test measures how well oxygen moves from the air into the blood. Resting energy expenditure. Participants will lie still for 30 minutes with a clear dome over their head. This test measures the calories their body burns at rest. 6-minute walk test. Participants will walk at their normal pace for 6 minutes. Their vital signs and blood oxygen levels will be checked. Hymecromone is a tablet taken by mouth. Participants will take 2 tablets every morning and 2 tablets every night for 12 weeks. Tests will be repeated at study visits.

NCT ID: NCT06323876 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

The Role of Quantitative CT and Radiomic Biomarkers for Precision Medicine in Pulmonary Fibrosis

Start date: May 2024
Phase:
Study type: Observational

This observational study involves obtaining 2 chest CT scans; a historical baseline CT within ±1 year of enrollment into PRECISIONS, and a follow-up CT (either historical or prospective) 12 months ± 180 days after the baseline CT. Many IPF patients will have a CT scan every 12 months for disease monitoring and cancer screening. Participants will have the option to share historical CTs only or they can choose to have a research CT done for the follow-up scan, if a scan for clinical purposes is not available.

NCT ID: NCT06317285 Not yet recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

A Study to Evaluate the Efficacy and Safety of GSK3915393 in Participants With Idiopathic Pulmonary Fibrosis (IPF)

Start date: April 1, 2024
Phase: Phase 2
Study type: Interventional

Idiopathic Pulmonary Fibrosis is a chronic lung disease which causes scarring of the lungs and difficulty in breathing. GSK3915393 is a new medicine, which is being tested in participants with IPF for the first time. The study will assess the safety and effectiveness of GSK3915393 in IPF participants.

NCT ID: NCT06304623 Completed - Pulmonary Fibrosis Clinical Trials

SVF for Treating Pulmonary Fibrosis Post COVID-19

SVFCOVID-19
Start date: May 5, 2020
Phase: Phase 1
Study type: Interventional

General description of the study This is a prospective, multicenter, expanded access interventional study of subjects recovered from COVID-19 pneumonia to assess their response to intravenous administration of adipose-derived autologous SVF. Primary objective The purpose of this study was to evaluate the safety of single intravenous injections of autologous adipose-derived SVF produced using the GID SVF-2 device system for the treatment of secondary respiratory distress associated with COVID-19. Secondary objective To evaluate the efficacy of the initial treatment with SVF IV.

NCT ID: NCT06275295 Not yet recruiting - Pulmonary Fibrosis Clinical Trials

A Retrospective Study of Transbronchial Cryobiopsy in the Diagnosis of Progressive Pulmonary Fibrosis

Start date: March 20, 2024
Phase:
Study type: Observational

The goal of this observational study is to learn about the diagnostic effectiveness, safety, and influencing factors of transbronchial cryobiopsy(TBLC) in progressive pulmonary fibrosis.

NCT ID: NCT06267183 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

A Clinical Study to Evaluate Safety, Tolerability and Pharmacokinetics of SV001 in Chinese Healthy Adult Volunteers.

Start date: January 12, 2024
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to evaluate safety, tolerability, PK and immunogenicity of SV001 compare to placebo in Chinese healthy adult volunteers.

NCT ID: NCT06265532 Recruiting - Clinical trials for Idiopathic Pulmonary Fibrosis

Collagen-targeted Positron Emission Tomography (PET) Imaging for Assessment of EGCG Effect

Start date: February 7, 2024
Phase: Phase 1
Study type: Interventional

The primary purpose of this substudy is to determine if collagen-targeted PET using the type 1 collagen-targeted PET probe, Gallium-68 (68Ga)-labeled collagen binding probe 8 (CBP8) can inform as to drug effect of EGCG and assist in dose selection.